HUMAN,ISPR - Résultats de recherche

Australie - anglais - Department of Health (Therapeutic Goods Administration)

humalog insulin lispro 100iu/ml injection multidose vial

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, solution - excipient ingredients: glycerol; sodium hydroxide; water for injections; hydrochloric acid; zinc oxide; dibasic sodium phosphate heptahydrate; metacresol - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

États-Unis - anglais - NLM (National Library of Medicine)

humalog- insulin lispro injection, solution

remedyrepack inc. - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - humalog is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. humalog is contraindicated: - during episodes of hypoglycemia - in patients who are hypersensitive to humalog or to any of its excipients. risk summary the limited available data with humalog in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . pregnant rats and rabbits were exposed to insulin lispro in animal reproduction studies during organogenesis. no adverse effects on embryo/fetal viability or morphology were observed in offspring of rats exposed t

États-Unis - anglais - NLM (National Library of Medicine)

humalog- insulin lispro injection, solution

remedyrepack inc. - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - humalog is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. humalog is contraindicated: - during episodes of hypoglycemia - in patients who are hypersensitive to humalog or to any of its excipients. pregnancy category b. all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. careful monitoring of glucose control is essential in these patients. therefore, female patients should be advised to tell

Malte - anglais - Medicines Authority

panzyga 100mg/ml solution for infusion (1g/10ml)

octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - human normal, immunoglobulin - solution for infusion - human normal immunoglobulin 100 mg/ml - immune sera and immunoglobulins

Malte - anglais - Medicines Authority

panzyga 100mg/ml solution for infusion (2.5g/25ml)

Malte - anglais - Medicines Authority

panzyga 100mg/ml solution for infusion (5g/50ml)

Malte - anglais - Medicines Authority

panzyga 100mg/ml solution for infusion (6g/60ml)

Malte - anglais - Medicines Authority

panzyga 100mg/ml solution for infusion (10g/100ml)

Malte - anglais - Medicines Authority

panzyga 100mg/ml solution for infusion (20g/20ml)

octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - human normal, immunoglobulin - solution for infusion - human normal immunoglobulin 100 mmol/ml - immune sera and immunoglobulins

Malte - anglais - Medicines Authority

panzyga 100mg/ml solution for infusion (30g/30ml)